Insights

Gathering insights about Augmenta Bioworks, Inc.…

Similar companies to Augmenta Bioworks, Inc.

Augmenta Bioworks, Inc. Tech Stack

Augmenta Bioworks, Inc. uses 5 technology products and services including Squarespace, Webpack, Google Fonts API, and more. Explore Augmenta Bioworks, Inc.'s tech stack below.

Squarespace
Content Management System
Webpack
Development
Google Fonts API
Font Scripts
Modernizr
Javascript Libraries
Adobe Fonts
Web Fonts

Media & News

Augbio is developing inhalable monoclonal antibody to treat COVID-19.
So, the Austin, Texas-based company teamed up with Augmenta Bioworks in Menlo Park, California, to develop an inhalable monoclonal antibody to treat COVID-19.
Oct 15, 2021 | www.fiercebiotech.com
Augbio partners with Catalent Pharma Solutions.
TFF and Augmenta are working with Catalent Biologics to conduct cell line development, drug substance manufacturing and scale-up efforts for AUG-3387 as the program advances through clinical development.
Oct 13, 2021 | finance.yahoo.com
Augbio is developing human-derived monoclonal antibodies for potential COVID-19 therapeutics on Nov 1st '20.
About the Development Agreement Between Augmenta Bioworks and TFF Pharmaceuticals In November 2020, Augmenta Bioworks and TFF Pharmaceuticals announced establishment of a worldwide Joint Development and Collaboration Agreement to develop novel commercial products incorporating Augmenta’s human-derived monoclonal antibodies (mAbs) for potential COVID-19 therapeutics.
Oct 13, 2021 | finance.yahoo.com
Augbio is developing human-derived monoclonal antibodies for potential COVID-19 therapeutics on Nov 1st '20.
In November 2020, Augmenta Bioworks and TFF Pharmaceuticals announced establishment of a worldwide Joint Development and Collaboration Agreement to develop novel commercial products incorporating Augmenta’s human-derived monoclonal antibodies (mAbs) for potential COVID-19 therapeutics.
Jul 29, 2021 | finance.yahoo.com
Augbio is developing novel commercial products incorporating Augmenta’s human-derived monoclonal antibodies for potential COVID-19 therapeutics on Nov 1st '20.
In November 2020, TFF and Augmenta announced the establishment of a joint development and collaboration agreement to develop novel commercial products incorporating Augmenta’s human-derived monoclonal antibodies (mAbs) for potential COVID-19 therapeutics.
Jun 25, 2021 | www.biopharma-reporter.com
Augbio is developing human-derived monoclonal antibodies for potential COVID-19 therapeutics on Nov 2nd '20.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company, and Augmenta Bioworks, Inc., a biotechnology company enabling breakthroughs in medicine through immune profiling, today jointly announce that both companies have entered into a worldwide Joint Development and Collaboration Agreement to develop novel commercial products incorporating Augmenta’s human-derived monoclonal antibodies (mAbs) for potential COVID-19 therapeutics.
Nov 02, 2020 | finance.yahoo.com

Augmenta Bioworks, Inc.'s Email Address Formats

Augmenta Bioworks, Inc. uses at least 1 format(s):

Augmenta Bioworks, Inc. Email Formats	Example	Percentage
First@augbio.com	John@augbio.com	50%
First@augbio.com	John@augbio.com	50%

Frequently Asked Questions

Where is Augmenta Bioworks, Inc.'s headquarters located?

Augmenta Bioworks, Inc.'s main headquarters is located at 3475 Edison Way, Menlo Park, California 94025, US. The company has employees across 1 continents, including North America.

What is Augmenta Bioworks, Inc.'s official website and social media links?

Augmenta Bioworks, Inc.'s official website is augbio.com and has social profiles on LinkedIn.

What is Augmenta Bioworks, Inc.'s SIC code NAICS code?

Augmenta Bioworks, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Augmenta Bioworks, Inc. have currently?

As of December 2025, Augmenta Bioworks, Inc. has approximately 1 employees across 1 continents, including North America. Key team members include Lab Manager: M. K.Biological Scientist: R. C.: C. E.. Explore Augmenta Bioworks, Inc.'s employee directory with LeadIQ.

What industry does Augmenta Bioworks, Inc. belong to?

Augmenta Bioworks, Inc. operates in the Biotechnology Research industry.

What technology does Augmenta Bioworks, Inc. use?

Augmenta Bioworks, Inc.'s tech stack includes SquarespaceWebpackGoogle Fonts APIModernizrAdobe Fonts.

What is Augmenta Bioworks, Inc.'s email format?

Augmenta Bioworks, Inc.'s email format typically follows the pattern of First@augbio.com. Find more Augmenta Bioworks, Inc. email formats with LeadIQ.

When was Augmenta Bioworks, Inc. founded?

Augmenta Bioworks, Inc. was founded in 2016.

Augmenta Bioworks, Inc.

Q: What is Augmenta Bioworks, Inc.'s official website and social media links?

Augmenta Bioworks, Inc.'s official website is augbio.com. Augmenta Bioworks, Inc. has social profiles on LinkedIn.

Q: How many employees does Augmenta Bioworks, Inc. have currently?

Augmenta Bioworks, Inc. has approximately 1 employees.

Q: What technology does Augmenta Bioworks, Inc. use?

Augmenta Bioworks, Inc.'s tech stack includes Adobe Fonts, Google Fonts API, Modernizr, Webpack, Squarespace.

Biotechnology ResearchUnited States0-1 Employees

Augmenta Bioworks discovers new therapeutics by harnessing the most powerful force in the fight against disease: natural human immunity. 

Our technology pinpoints the protective immune response of individuals and translates discoveries into therapies.

Company Overview

Headquarters: 3475 Edison Way, Menlo Park, California 94025, US
Website: augbio.com
SIC Code: 8733 - Noncommercial Research Organizations
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2016
Employees: 0-1

Media & News

Funding & Financials

$1M$10M
Augmenta Bioworks, Inc.'s revenue is estimated to be in the range of $1M$10M

Funding & Financials

$1M$10M
Augmenta Bioworks, Inc.'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Augmenta Bioworks, Inc.

Benchling

Eurofins

Twist Bioscience

Arzeda

Amyris

Geno

Augmenta Bioworks, Inc. Tech Stack

Media & News

Augbio is developing inhalable monoclonal antibody to treat COVID-19.

Augbio partners with Catalent Pharma Solutions.

Augbio is developing human-derived monoclonal antibodies for potential COVID-19 therapeutics on Nov 1st '20.

Augbio is developing human-derived monoclonal antibodies for potential COVID-19 therapeutics on Nov 1st '20.

Augbio is developing novel commercial products incorporating Augmenta’s human-derived monoclonal antibodies for potential COVID-19 therapeutics on Nov 1st '20.

Augbio is developing human-derived monoclonal antibodies for potential COVID-19 therapeutics on Nov 2nd '20.

Augmenta Bioworks, Inc.'s Email Address Formats

Frequently Asked Questions

Where is Augmenta Bioworks, Inc.'s headquarters located?

What is Augmenta Bioworks, Inc.'s official website and social media links?

What is Augmenta Bioworks, Inc.'s SIC code NAICS code?

How many employees does Augmenta Bioworks, Inc. have currently?

What industry does Augmenta Bioworks, Inc. belong to?

What technology does Augmenta Bioworks, Inc. use?

What is Augmenta Bioworks, Inc.'s email format?

When was Augmenta Bioworks, Inc. founded?

Augmenta Bioworks, Inc.

Company Overview

Media & News

Augbio is developing inhalable monoclonal antibody to treat COVID-19.

Augbio partners with Catalent Pharma Solutions.

Augbio is developing human-derived monoclonal antibodies for potential COVID-19 therapeutics on Nov 1st '20.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?